Renal Failure News and Research

RSS

Renal failure or kidney failure is where the kidneys fail to function adequately. Renal failure is divided in acute and chronic forms; either form may be due to a large number of other medical problems.

Study to test NAC and aspirin for people diagnosed with bipolar disorder

A commonly available pharmaceutical drug with anti-inflammatory properties and a nutritional supplement thought to have antioxidant effects are now being tested at The University of Texas Health Science Center at Houston (UTHealth) as add-on therapies for people diagnosed with bipolar disorder.

21 Jun 2012

Pre-operative aspirin therapy may reduce risk of acute kidney failure after CABG surgery

Aspirin taken for five days before a heart operation can halve the numbers of patients developing post-operative acute kidney failure, according to research presented at the European Anaesthesiology Congress in Paris.

11 Jun 2012

HDL to offer testing services based on Critical Diagnostics' Presage ST2 Assay

Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases and Health Diagnostic Laboratory, Inc. (HDL, Inc.), announced today an agreement under which HDL, Inc. will soon offer ST2 testing services based on Critical Diagnostics' Presage ST2 Assay.

5 Jun 2012

Lilly, Kowa announce results from PREVAIL U.S. study

Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company today announced results of the PREVAIL U.S. study (Pitavastatin compaREd with praVAstatin In Lowering LDL-C in the U.S.) which evaluated the efficacy of LIVALO (pitavastatin) 4 mg compared with pravastatin 40 mg in reducing low-density lipoprotein cholesterol (LDL-C), the primary endpoint, as well as effects on other lipid parameters and lipoprotein particles in adult patients with primary hyperlipidemia or mixed dyslipidemia.

2 Jun 2012

IU scientists successfully transplant primary kidney cells intravenously to treat renal failure

Indiana University School of Medicine scientists have successfully transplanted primary kidney cells intravenously to treat renal failure in rats, pointing the way to a possible future alternative to kidney transplants and expensive dialysis treatments in humans.

1 Jun 2012

Intensive glucose control associated with reduced risk of albuminuria

A review of data from seven clinical trials suggests that intensive glucose control is associated with reduced risk of microalbuminuria and macroalbuminuria (conditions characterized by excessive levels of protein in the urine usually resulting from damage to the filtering units of the kidneys), according to a report published in the May 28 issue of Archives of Internal Medicine, a JAMA Network publication.

29 May 2012

Tulane to initiate XM-ONE clinical trial in kidney transplantation

Tulane University Hospital, New Orleans, LA, USA will in May start a prospective trial in Kidney Transplantation investigating the potential of cross match XM-ONE as part of the risk assessment of their patients.

28 May 2012

Zytoprotec completes PD-protec Phase I/II trial on kidney failure

Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec.

24 May 2012

FMCNA announces new educational resources to enhance RightStart

Fresenius Medical Care North America (FMCNA), the nation's leading network of dialysis facilities, announced today new educational resources to enhance RightStart™, its innovative program designed to educate and empower new dialysis patients.

24 May 2012

Phase I/II clinical trial of novel dialysate completed by Zytoprotec

Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec™. The product is developed to improve the treatment of patients with kidney failure.

23 May 2012

ACE2 molecule now protects major organs in diabetic patients

ACE2, a molecule that has been shown to prevent damage in the heart, is now proving to be protective of the major organs that are often damaged in diabetic patients.

17 May 2012

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.

16 May 2012

Excess protein in urine test predicts renal failure in patients with severe sepsis

Henry Ford Hospital researchers have found that the presence of excess protein in a common urine test is an effective prognostic marker of acute renal failure in patients with severe sepsis.

14 May 2012

Patients with mitral regurgitation live longer after surgery

Patients with mitral regurgitation, a type of valvular heart disease common in the elderly, are living longer after surgery, Yale School of Medicine researchers report in the journal Circulation: Cardiovascular Quality and Outcomes.

11 May 2012

FDA ADAC recommends approval of Gilead’s Truvada for HIV

Gilead Sciences, Inc. today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted to support approval of once-daily oral Truvada(emtricitabine and tenofovir disoproxil fumarate) to reduce the risk of HIV-1 infection among uninfected adults, an HIV prevention strategy called pre-exposure prophylaxis or PrEP.

11 May 2012

A Better Method for Diagnosing Kidney Disease

Assessing glomerular filtration rate (GFR) using kidney filtration markers in blood is the standard means for determining kidney function, diagnosing kidney disease and measuring its progression. A higher filtration rate indicates healthy kidney function, while a lower rate points to various stages of kidney disease. A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that the new CKD-EPI equation for calculating GFR is a better predictor of risk for kidney disease and death compared to the most widely used method. The findings suggest that switching to the CKD-EPI equation for calculating GFR could focus efforts more efficiently, and improve assessment of patient future risk and treatment of kidney disease. The study is published in the May 9 edition of JAMA.

10 May 2012

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion Pharmaceuticals Inc. today announced results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to LATUDA.

10 May 2012

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).

7 May 2012

TGA approves Ikaria’s LUCASSIN to treat Hepatorenal Syndrome Type 1

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, announced today the approval of LUCASSIN (terlipressin) by the Therapeutic Goods Administration (TGA) of Australia.

24 Apr 2012

EMA CHMP recommends approval of AMAG’s ferumoxytol

AMAG Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the approval of ferumoxytol, an intravenous (IV) iron therapy, for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease.

21 Apr 2012